Detalhe da pesquisa
1.
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
Gynecol Oncol
; 185: 128-137, 2024 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38412736
2.
A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.
Gynecol Oncol
; 171: 106-113, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36868112
3.
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
Gynecol Oncol
; 170: 186-194, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36706645
4.
Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era.
Br J Cancer
; 127(1): 79-83, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35361918
5.
Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study.
Int J Gynecol Cancer
; 32(6): 761-768, 2022 06 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35086926
6.
Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups.
BMC Surg
; 22(1): 1, 2022 Jan 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34996419
7.
Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study.
Gut
; 69(4): 681-690, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31780575
8.
Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
Lancet Oncol
; 21(9): 1173-1187, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32758455
9.
Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial.
Br J Cancer
; 122(7): 957-962, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32015513
10.
Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).
Gynecol Oncol
; 159(1): 256-263, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32712155
11.
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Lancet Oncol
; 19(8): 1094-1106, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30042063
12.
Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
Gynecol Oncol
; 148(1): 36-41, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29107348
13.
Corrigendum to "A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer".
Gynecol Oncol
; 175: 194, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37271667
14.
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial.
Lancet Healthy Longev
; 5(3): e182-e193, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38432247
15.
[French national standard for the treatment of squamous cell carcinoma of upper aero-digestive tract - General principles of treatment]. / Référentiel national de traitement des carcinomes épidermoïdes des voies aérodigestives supérieures Principes généraux de traitement.
Bull Cancer
; 111(4): 393-415, 2024 Apr.
Artigo
em Francês
| MEDLINE | ID: mdl-38418334
16.
Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Invest New Drugs
; 31(5): 1207-16, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23397499
17.
Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010-02).
Eur J Cancer
; 178: 114-127, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36434888
18.
Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.
Eur J Cancer
; 183: 24-37, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36796234
19.
Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.
Eur J Cancer
; 162: 138-147, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34995900
20.
Responsiveness of EORTC QLQ-C30, QLQ-CR38 and FACT-C quality of life questionnaires in patients with colorectal cancer.
Health Qual Life Outcomes
; 9: 70, 2011 Aug 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-21859485